Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio Inc (NUVB)
:NUVB
Earnings Data
Report Date
Nov 05, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.15Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlights significant progress towards the potential approval and launch of taletrectinib, underpinned by strong clinical data and a solid financial position. However, there are concerns about the increased net loss and potential challenges in achieving rapid market penetration.Company Guidance
Taletrectinib's Potential FDA Approval
Taletrectinib is expected to receive FDA approval by June 23, 2025, marking a significant milestone for Nuvation Bio as it transitions to a commercial-stage company.
Clinical Trial Success for Taletrectinib
Taletrectinib demonstrated an 89% overall response rate in treatment-naïve patients, with a median progression-free survival of 46 months and a median duration of response of 44 months.
Positive Safety Profile
Taletrectinib has shown a low discontinuation rate of 6.5% and manageable adverse events, making it a well-tolerated treatment option.
Strong Financial Position
Nuvation Bio ended the quarter with $461.7 million in cash and a $250 million non-dilutive financing agreement with Sagard Healthcare Partners.
Strategic Commercial Readiness
Nuvation Bio has a veteran commercial team with a focused strategy to launch taletrectinib effectively and efficiently upon approval.
NUVB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NUVB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | $2.35 | $2.34 | -0.43% |
May 07, 2025 | $2.04 | $2.10 | +2.94% |
Mar 06, 2025 | $1.89 | $2.02 | +6.88% |
Nov 06, 2024 | $2.54 | $2.62 | +3.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Nuvation Bio Inc (NUVB) report earnings?
Nuvation Bio Inc (NUVB) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).
What is Nuvation Bio Inc (NUVB) earnings time?
Nuvation Bio Inc (NUVB) earnings time is at Nov 05, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NUVB EPS forecast?
NUVB EPS forecast for the fiscal quarter 2025 (Q3) is -0.17.